Repligen (NASDAQ:RGEN) Shares Gap Down – Should You Sell?

Repligen Co. (NASDAQ:RGEN)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $149.21, but opened at $145.00. Repligen shares last traded at $148.09, with a volume of 203,613 shares trading hands.

Analyst Ratings Changes

A number of research firms have recently commented on RGEN. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Stephens reiterated an “overweight” rating and set a $170.00 price target on shares of Repligen in a research note on Tuesday, July 30th. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Down 4.6 %

The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 549.92, a PEG ratio of 4.24 and a beta of 0.95. The firm has a fifty day moving average price of $144.24 and a 200 day moving average price of $147.63. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same quarter last year, the business earned $0.53 earnings per share. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. As a group, sell-side analysts expect that Repligen Co. will post 1.45 EPS for the current fiscal year.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently modified their holdings of RGEN. Norden Group LLC raised its stake in Repligen by 1,711.6% during the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after purchasing an additional 36,663 shares during the period. Artemis Investment Management LLP increased its position in Repligen by 33.8% during the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after purchasing an additional 42,380 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Repligen by 30.2% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after buying an additional 6,705 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Repligen by 21.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock valued at $61,767,000 after buying an additional 59,903 shares in the last quarter. Finally, Swedbank AB purchased a new stake in Repligen during the first quarter worth approximately $5,518,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.